FDA Policy for REMS Reqmts during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.
Read the Policy now
Related Education Resources.
All Resources2020 Virtual Conference: Presentation and Workshop Slides
Topics: Communication, Conference, Personal Development, Pharma Industry
Presentation
Members
GCSG App User Guide
Topic: Conference
Conference Training
Free
Envisioning the Future of Clinical Supply Chains in the Next 10 Years
Topic: Supply Chain
Executive Summary
Members
